NCT03983473

Brief Summary

The MICROSPA project aims to compare gut microbiota, serum cytokines, and PBMC of patients suffering from Crohn's disease (CD) associated or not to spondylarthritis (SpA). 3 groups of patients will be analyzed: patients suffering from CD alone, patients suffering from SpA alone, patients suffering from CD and SpA. One group of healthy controls will be analysed as a comparator. Fecal microbiota will be determined by bacteriome, virome and fungome NGS sequencing

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
240

participants targeted

Target at P75+ for not_applicable

Timeline
8mo left

Started Nov 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress88%
Nov 2021Dec 2026

First Submitted

Initial submission to the registry

May 22, 2019

Completed
21 days until next milestone

First Posted

Study publicly available on registry

June 12, 2019

Completed
2.4 years until next milestone

Study Start

First participant enrolled

November 16, 2021

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 4, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 16, 2026

Last Updated

February 3, 2026

Status Verified

January 1, 2026

Enrollment Period

5 years

First QC Date

May 22, 2019

Last Update Submit

January 30, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • Alpha and Beta diversity of Fecal bacteriome

    Alpha (number of species) and Beta diversity (distribution of species)

    + 6 months

  • Alpha and Beta diversity of Fecal fungome

    Alpha (number of species) and Beta diversity (distribution of species)

    + 6 months

  • Alpha and Beta diversity of Fecal virome

    Alpha (number of species) and Beta diversity (distribution of species)

    + 6 months

Study Arms (4)

Crohn's disease

OTHER

Patients suffering from established Crohn 's disease without spondyloarthritis

Other: Microbiota Sequencing

Spondyloarthritis

OTHER

Patients with established spondyloarthritis without Crohn 's disease

Other: Microbiota Sequencing

Crohn + spondyloarthritis

OTHER

Patients suffering from both spondyloarthritis and Crohn 's disease

Other: Microbiota Sequencing

Healthy controls

OTHER

Patients without spondyloarthritis and Crohn 's disease

Other: Microbiota Sequencing

Interventions

virome, bacteriome, fungome NGS sequencing

Crohn + spondyloarthritisCrohn's diseaseHealthy controlsSpondyloarthritis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years.
  • Patients will be recruited according to 3 groups:
  • Patients with Crohn's disease and axial spondyloarthritis according to the criteria below.
  • Patient with the ability to give free and express informed consent.

You may not qualify if:

  • History of colonic resection
  • Taking antibiotics or colon preparation for colonoscopy within 8 weeks before stool collection (Temporary contraindication = removal possible before colic or first bowel preparation after the start of colonic preparation).
  • Ostomy at the time of sampling
  • BMI\> 30
  • extreme diet
  • unbalanced diabetes
  • Pregnant woman
  • Patient under guardianship, under curatorship or under the protection of justice Contacts/Locations Central Contact

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Central Hospital

Nancy, Lorraine, 54500, France

RECRUITING

Saint Antoine Hospital

Paris, 75012, France

RECRUITING

MeSH Terms

Conditions

Crohn DiseaseSpondylarthritis

Condition Hierarchy (Ancestors)

Inflammatory Bowel DiseasesGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal DiseasesSpondylitisSpinal DiseasesBone DiseasesMusculoskeletal DiseasesArthritisJoint Diseases

Central Study Contacts

Laurent MD PEYRIN-BIROULET, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

May 22, 2019

First Posted

June 12, 2019

Study Start

November 16, 2021

Primary Completion (Estimated)

November 4, 2026

Study Completion (Estimated)

December 16, 2026

Last Updated

February 3, 2026

Record last verified: 2026-01

Locations